Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Woodward Pharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq/mL
Details : Sodium Acetate-generic Injection is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake.
Product Name : Sodium Acetate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2024
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Woodward Pharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Microscopic and elemental analyses determined the presence of particulates in Maxivial (sodium acetate) injection that is composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Product Name : Maxivial
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Sodium Acetate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable